In 2022, several new patient-derived models of FGFR2 fusion-positive ICC emerged, though exclusive of organoids, and were used to identify a new combination strategy with EGFR inhibition20; given the known crosstalk and interaction between FGFR and EGFR signaling, this combination strategy shows promise and is being explored clinically. This evidence concerns the gene EGFR and intrahepatic cholangiocarcinoma.